Fundacion Clinic per a la Recerca Biomédica
clinicbarcelona.orgTotal trials
60
Active
24
Phase 3
6
Total enrollment
16,458
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 33 of 33 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Moxifloxacin | — | — | — | — | — | 2 | |
| Saline solution | — | — | — | — | — | 1 | |
| Cefaclor | — | — | — | — | — | 1 | |
| Ciprofloxacin | — | — | — | — | — | 1 | |
| Clindamycin Oral | — | — | — | — | — | 1 | |
| Dicloxacillin Oral | — | — | — | — | — | 1 | |
| Fusidic Acid Only Product in Oral Dose Form | — | — | — | — | — | 1 | |
| Fusidic Acid Only Product in Parenteral Dose Form | — | — | — | — | — | 1 | |
| Levofloxacin Oral | — | — | — | — | — | 1 | |
| Linezolid Oral | — | — | — | — | — | 1 | |
| Linezolid Injectable Product | — | — | — | — | — | 1 | |
| Moxifloxacin Injectable Product | — | — | — | — | — | 1 | |
| Rifampicin Only Product in Oral Dose Form | — | — | — | — | — | 1 | |
| Rifampicin Only Product in Parenteral Dose Form | — | — | — | — | — | 1 | |
| Sulfamethoxazole / Trimethoprim Oral Tablet [Bactrim] | — | — | — | — | — | 1 | |
| Sulfamethoxazole / Trimethoprim Injectable Product | — | — | — | — | — | 1 | |
| Tedizolid Oral | — | — | — | — | — | 1 | |
| Amoxicillin | — | — | — | — | — | 1 | |
| Sex hormones and modulators of the genital system. | — | — | — | — | — | 1 | |
| Estradiol + Progesterone | — | — | — | — | — | 1 | |
| Ovitrelle | — | — | — | — | — | 1 | |
| Darbepoetin | — | — | — | — | — | 1 | |
| Radiotracer | — | — | — | — | — | 1 | |
| Atezolizumab and Bevacizumab | — | — | — | — | — | 1 | |
| ARI0002h | — | — | — | — | — | 1 | |
| Autologous Tolerogenic Dendritic cells | — | — | — | — | — | 2 | |
| CD5CAR-CBNK | — | — | — | — | — | 1 | |
| 763SIP8/MPLA-5 vaccine | — | — | — | — | — | 1 | |
| ARI0003 | — | — | — | — | — | 1 | |
| Liquid biopsy | — | — | — | — | — | 2 | |
| Methylomics | — | — | — | — | — | 1 | |
| RNA sequencing | — | — | — | — | — | 1 | |
| Spatial transcriptomics | — | — | — | — | — | 1 |
Next readouts
- 2025-04-15
- 2025-06
- 2025-12
- 2026-03-31
- 2026-09-01
- 2026-11-20
- 2026-12
- 2026-12-30
- 2027-08
- 2028-03
Top conditions
- HIV3
- Nevi and Melanomas3
- Hepatitis C2
- Airway Management2
- Kidney Transplant Rejection2
- Melanoma (Skin Cancer)2
- Hepatocellular Carcinoma2
- HIV-1-infection2
Frequently asked questions about Fundacion Clinic per a la Recerca Biomédica
- How many clinical trials does Fundacion Clinic per a la Recerca Biomédica have on ClinicalTrials.gov?
- Fundacion Clinic per a la Recerca Biomédica is listed as the lead sponsor on 60 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fundacion Clinic per a la Recerca Biomédica's trials are in Phase 3?
- 6 of Fundacion Clinic per a la Recerca Biomédica's trials are in Phase 3, spread across 33 active drug programs.
- What therapeutic areas does Fundacion Clinic per a la Recerca Biomédica focus on?
- Fundacion Clinic per a la Recerca Biomédica's most-studied conditions on ClinicalTrials.gov are HIV, Nevi and Melanomas, Hepatitis C, Airway Management, Kidney Transplant Rejection.
- When are Fundacion Clinic per a la Recerca Biomédica's next clinical trial readouts?
- Fundacion Clinic per a la Recerca Biomédica has 10 upcoming primary-completion readouts tracked here; the soonest is “First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma”, expected around 2025-04-15.